Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Freek Verheugt,
Dr. Antonio Miguel Dans
Presenter | see Discussant report
Antonio Miguel Dans (Philippines)
List of Authors: Dans AL, Connolly S, Brückmann M, Ezekowitz M, Wallentin L, Yang S, Reilly P, Yusuf S
Background and Objectives: The RELY trial compared 2 doses of Dabigatran Etexilate (DE) to warfarin in 18,113 patients with atrial fibrillation (AF). Results showed that the 150 mg bid dose (DE 150) was superior, and the 110 mg bid dose (DE 110) non-inferior to warfarin in preventing stroke and systemic embolism (SSE). Many patients with AF suffer from conditions that require concomitant antiplatelet drugs that may interact with DE. It is therefore important to assess the efficacy and safety of DE vs warfarin in those receiving or not receiving other antiplatelets. Methods: In this post-hoc analysis, we compared the efficacy and safety of DE 110 and DE 150 to warfarin, in subgroups of patients with and without concomitant antiplatelet use during the study. The main efficacy outcome was SSE and the main safety outcome was major bleeding (MB). We also compared major bleeding rates in patients with and without concomitant antiplatelets, adjusting for known risk factors for bleeding. Results: A total of 6952 patients (38.4%) received concomitant ASA or clopidogrel during the study. Use of other antiplatelets was negligible. As in the main study results, DE 110 mg bid was non-inferior to warfarin in terms of the primary endpoint of SSE. This was true whether patients were on concomitant antiplatelets (HR=0.93, 95%CI:0.70-1.25) or not (HR=0.87, 95%CI:0.66-1.15; p for interaction= 0.7377). In terms of the main safety outcome of major bleeding, DE 110 was superior to warfarin. This effect was also unaffected by concomitant antiplatelet use (HR=0.82; 95%CI: 0.67-1.00 for patients on antiplatelets; HR=0.79; 95%CI: 0.64-0.96 for patients without antiplatelets; p for interaction=0.7945). The higher dose of dabigatran (DE 150) was superior to warfarin in terms of the primary outcome of SSE, particularly among patients who were not on antiplatelets (HR=0.52; 95%CI:0.38-0.72). This effect seemed to diminish when concomitant antiplatelets were given (HR=0.80; 95%CI:0.59-1.08), but the difference was not statistically significant (p for interaction = 0.0578), especially after correction for multiplicity of analyses. With respect to MB, DE 150 was similar to warfarin regardless of concomitant antiplatelet use (HR=0.93, 95%CI:0.76-1.12 for patients on antiplatelets; HR=0.94, 95%CI:0.78-1.15 for patients without antiplatelets; p for interaction=0.8746). Overall, the rates of major bleeding increased when antiplatelets were given concomitantly with anticoagulants (HR=1.60, 95% CI=1.41-1.81 after adjustment for age, gender, warfarin experience, systolic BP, coronary artery disease, heart failure, hypertension, diabetes, prior TIA, creatinine clearance and statin use). The relative increase was consistent whether patients were on DE 110, DE 150 or warfarin, but the absolute risks were lowest on DE 110. These results were unaffected by duration of antiplatelet use (<50% or >50% of the trial duration) or number of antiplatelets used (aspirin alone, clopidogrel alone, or the 2 in combination). Conclusion: Concomitant use of aspirin or clopidogrel increased the relative risks for bleeding in all treatment arms of the RE-LY study. However, the lowest absolute risk for bleeding was noted on DE 110. The relative advantages of DE 110 and DE 150 over warfarin (seen in the main trial results) were unaffected by concomitant antiplatelet use. Discussant | see Presenter abstract
Freek Verheugt (Netherlands)Presentation webcastPresentation slides
709009 - 709010
Clinical Trial Update I - Drug treatment
© 2017 European Society of Cardiology. All rights reserved